Background
==========

In Germany, there is still a considerable discrepancy between the number of organs available for transplantation and patients on waiting lists for kidney transplantation. This causes an increase in the patients' waiting periods until transplantation as well as their numerical mortality rates \[[@b1-anntransplant-23-836]--[@b4-anntransplant-23-836]\]. For many patients, early transplantation means a reduction in the mortality risk and an improvement of their quality of life \[[@b5-anntransplant-23-836]--[@b7-anntransplant-23-836]\]. The mean waiting time for a renal transplant, depending on the blood group, ranged between 62 and 90 months for German patients transplanted in 2016 \[[@b3-anntransplant-23-836]\]. The severe shortage of organs available for standard transplantation has led to an increase in living-donor kidney transplants on the one hand, and increased acceptance of marginal donor organs on the other. Feasible marginal donor strategies include the use of double-kidney transplants, including organs from elderly donors with an already reduced renal function \[[@b8-anntransplant-23-836],[@b9-anntransplant-23-836]\], or the transplantation of organs derived from expanded criteria donors (ECDs) \[[@b10-anntransplant-23-836]--[@b12-anntransplant-23-836]\]. In addition, the transplantation of organs from donors with a history of acute kidney injury (AKI) is also possible, and is increasingly utilized \[[@b13-anntransplant-23-836]\]. It is still the case that kidneys from donors with AKI are considered suboptimal and refused, since the chance of full recovery of kidney function is difficult to assess and the concerns about successful transplantation have remained until today \[[@b14-anntransplant-23-836]--[@b16-anntransplant-23-836]\]. Thus, the use of organs from donors with AKI has been the subject of persistent controversy. While some studies have reported comparable rates of graft and patient survival after transplantation of kidneys from standard donors and those with AKI \[[@b17-anntransplant-23-836]--[@b21-anntransplant-23-836]\], others have described more unfavorable results \[[@b22-anntransplant-23-836]\]. Few studies on the long-term outcome of transplantation of organs donors with AKI are currently available \[[@b14-anntransplant-23-836],[@b17-anntransplant-23-836],[@b21-anntransplant-23-836]\]. Therefore, the aim of the present retrospective study was to assess kidney graft and patient survival rates and parameters of organ function after AKI-derived transplantation in a large-cohort German study.

Material and Methods
====================

The present study included all patients who received a kidney transplant from a brain-dead organ donor at the Transplantation Center of Bochum, Germany in the period between January 2005 and March 2016. The pre-operative cross-match analysis was negative in all cases. Living-donor and double-kidney transplants were excluded from the study. The analysis comprised patients' files, laboratory values derived from the electronic databank as well as the evaluation of EUROTRANSPLANT donor reports. Based on the donors' renal function, 3 groups were formed and compared: (i) the AKI-1 group, consisting of 214 patients who received a transplant from a donor with AKI combined with a peak serum creatinine (SCr) level of 1.1--2 mg/dL; (ii) the AKI-2 group, 89 patients with transplants from donors with AKI and peak SCr level of \>2 mg/dL; and (iii) the Non-AKI group, 339 patients who received transplants from donors with normal kidney function (SCr \<1.1 mg/dL). Data collected from the donors' medical records included age, gender, body mass index (BMI), cause of death, history of hypertension or diabetes, SCr, ECD status, and cardiac arrest. We analyzed the following recipient parameters: patient and graft survival, SCr, estimated glomerular filtration rate (eGFR), the rate of biopsy-proven acute rejection episodes at one year, and the rates of delayed graft function (DGF) and primary non-function (PNF).

The criteria for donors were defined based on EUROTRANSPLANT donor reports, which included age, gender, cause of death, BMI, SCr at the time point of admission, SCr maximum value, latest determined SCr value prior to organ removal, eGFR according to the Cockroft-Gault formula, and presence of diabetes mellitus and hypertension. Further criteria were previous cardiac arrest, smoking status, as well as catecholamine therapy. Group assignments were performed according to ECD and standard criteria donor (SCD). In accordance with the definition of the United Network of Organ Sharing, ECDs were defined as brain-dead organ donors, 60 years of age or older; or organ donors between 50 and 59 years fulfilling at least 2 of the 3 criteria of cerebrovascular cause of death, a last SCr value \>1.5 mg/dl, or history of hypertension \[[@b11-anntransplant-23-836]\].

Analysis of recipient criteria included the following parameters: age, gender, BMI, duration and type of dialysis, cold ischemia time, duration of surgery, human leucocyte antigen (HLA) mismatch, cytomegalovirus serological status, panel-reactive antibodies, as well as induction and maintenance immunosuppression.

The primary objective of the study was to calculate patient and graft survival at 1, 3, and 5 years. Kidney graft function was assessed using eGFR rates according to the Cockroft-Gault formula. Rejections were graded according to the Banff classification. Further outcome measures were the rates of DGF and PNF, as well as the duration of hospitalization. DGF was defined as the need for one or more hemodialysis treatments within the first week after transplantation \[[@b23-anntransplant-23-836]\]. Patients whose grafts never functioned were defined as having PNF.

Renal transplant failure was defined as patient death with a functioning graft, allograft nephrectomy, or the need for permanent dialysis or re-transplantation.

For statistical analysis, the chi-square test and Fisher's exact test were used to compare categorical variables. Continuous variables were compared between 2 groups using the Mann-Whitney U test, while the Kruskal-Wallis test was used to compare more than 2 groups. Patient and graft survival were calculated using the Kaplan-Meier method based on the log-rank test. All p-values \<0.05 were considered statistically significant. Analysis was performed using SPSS version 23 (SPSS Inc, Chicago, IL).

The study was approved by the local ethics board of the Faculty of Medicine at the Ruhr University of Bochum, Germany (registry number: 17-6106).

Results
=======

In total, 642 kidney transplant recipients were included in this study. Among these, 303 (47.2%) received grafts from donors who suffered from renal functional impairment. The donor SCr was 1.1--2.0 mg/dl in 214 patients (33.3%; AKI-1 group), \>2 mg/dl in 89 patients (13.9%; AKI-2 group), and within normal values in 339 patients (52.8%; Non-AKI group). In addition, among the 642 donor kidneys, 331 (51.6%) had been classified as ECD organs and were mostly transplanted to patients in the AKI-1 group (n=125; 58.4%). The rate of ECD organs was 49.3% (n=167) in the Non-AKI group and 43.8% (n=39) in the AKI-2 group.

The characteristics of all organ donors are shown in [Table 1](#t1-anntransplant-23-836){ref-type="table"}. The donors of the AKI-2 group were significantly younger (mean age, 49.3±16.3 years) than those of the AKI-1 (mean age: 56.9±15.7 years) and Non-AKI groups (mean age: 55.3±16.1 years; p\<0.001). Regarding the gender distribution of the donors, a significantly higher portion of male donor organs was used for transplantation in both AKI groups compared to the Non-AKI group (p\<0.001). In addition, donors in the AKI-1 and AKI-2 groups had significantly higher BMI values than those in the Non-AKI group (p\<0.001). Consistent with the intergroup differences in donor characteristics, significant differences in kidney function parameters were observed. The eGFR of the organ donors, measured at admission, was significantly lower in the AKI-1 (90.5±37.1 mL/min) and AKI-2 groups (90.3±40.7 mL/min) than in the non-AKI group (114.8±40.2 mL/min). While regular improvement in kidney function was observed in the non-AKI group during the period between admission and organ removal (mean eGFR: 120.5±49.2 mL/min), a significant drop in eGFR values was noted in both AKI groups during the same period (AKI-1 group: 80.3±39.7 mL/min; AKI-2 group: 47.2±20.9 mL/min). Renal replacement therapy with hemofiltration was required in 9 organ donors (10.1%) in the AKI-2 group, and 1 (0.5%) in the AKI-1 group. The highest measured mean SCr values were 3.2±1.5 mg/dL in the AKI-2, 1.4±0.2 mg/dL in the AKI-1, and 0.8±0.2 mg/dL in the Non-AKI groups. Moreover, previous cardiac arrests requiring cardiopulmonary resuscitation were significantly more frequent in the AKI-1 and AKI-2 groups, with the highest frequency observed in the AKI-2 group. The requirement for catecholamine therapy, however, did not differ between the 3 groups. With respect to previously existing diseases in the donor, arterial hypertension and diabetes mellitus were most frequent in the AKI-1 group. No significant differences were noted between the groups regarding cause of death, the use of perfusion solutions, or the number of smokers.

The characteristics of all organ recipients are shown in [Table 2](#t2-anntransplant-23-836){ref-type="table"}. Most characteristics did not differ significantly between the 3 groups, with the exception of HLA mismatch and the duration of surgery. Regarding HLA mismatch, recipients in the Non-AKI group had significantly better matching rates. Similarly, our analysis showed a significantly longer duration of surgery in the AKI-1 and AKI-2 groups (p=0.004).

All patients received antibody induction therapy in combination with calcineurin inhibitors, mycophenolate mofetil, and tapered steroids. In most patients (76.8%), antithymocyte globulin (1.5 mg/kg per day, 1--5 times) was administered for induction therapy. In other cases, basiliximab (20 mg, twice) was used. Tacrolimus was typically started on posttransplant day 1, except when an organ from an AKI-donor was used. In such cases, tacrolimus therapy initiation was delayed by 3--5 days depending on renal function. Dosages were adjusted to achieve whole blood trough concentrations of 8--12 ng/ml for the first 2 months and 5--8 ng/ml thereafter. Mycophenolate mofetil was given orally from postoperative day 1 in a dose of 2 g/day. The steroid regimen consisted of 500 mg prednisolone intraoperatively and 250 mg prednisolone on posttransplant day 1. Thereafter, steroids were steadily tapered from 20 mg on day 2 to 5 mg by day 60.

The mean follow-up duration was 55.82±34.97 months. Patient survival at 1 year was 95.3%, 91.6%, and 92.1% in the Non-AKI, AKI-1, and AKI-2 groups, respectively. Patient survival at 5 years was 80.5%, 79.4%, and 86.8%. Log-rank testing showed no statistically significant differences (p=0.248) in survival at 1 and 5 years ([Figure 1A](#f1-anntransplant-23-836){ref-type="fig"}). The 1-year survival rates of the kidney allografts were 88.5%, 79.4% and 83.1% in the Non-AKI, AKI-1, and AKI-2 groups, respectively, while the 5-year graft survival was 71.1%, 67.8% and 71.7%, respectively (log-rank test p=0.255). No significant difference was observed at either time point ([Figure 1B](#f1-anntransplant-23-836){ref-type="fig"}).

The results of kidney transplantations performed in the 3 groups are shown in [Table 3](#t3-anntransplant-23-836){ref-type="table"}. DGF was significantly more frequent in the AKI-2 group (44.9%) than in the Non-AKI (28.6%) and AKI-1 groups (29.9%; p=0.011). PNF was similarly frequent in the AKI-1 and AKI-2 groups (10.3% and 10.1%, respectively) but was less frequent in the Non-AKI group (5.6%). No statistically significant differences were noted between the 3 groups (p=0.09). The cumulative biopsy-proven acute rejection rates (including borderline Banff changes) at 1 year were 26.3%, 29.4% and 25.8% in the Non-AKI, AKI-1, and AKI-2 groups, respectively. There was no difference between the groups.

The period of hospitalization was comparable in the 3 groups. The mean SCr value at discharge from inpatient treatment was 2.3±1.7 mg/dL and 2.3±1.2 mg/dL in the AKI-1 and AKI-2 groups, respectively, poorer than the values in the Non-AKI group (2.1±1.6 mg/dL). A statistically significant difference was only noted between the AKI-2 and Non-AKI groups (p=0.04). The mean SCr values at 1, 3, and 5 years were 2.1±1.7, 2.2±2.1, and 1.9±1.3 mg/dL, respectively, in the AKI-1 group; 2.0±1.5, 2.3±2.2, and 1.7±0.7 mg/dL, respectively, in the AKI-2 groups; and 1.8±1.1, 1.7±0.8, and 1.7±0.9 mg/dL, respectively, in the Non-AKI group. Only the 3-year SCr value in the Non-AKI group was significantly different from that in the AKI groups (p\<0.001).

[Figure 2](#f2-anntransplant-23-836){ref-type="fig"} shows the eGFR rates in all 3 groups at 1, 3, and 5 years. The Non-AKI group showed a significantly higher mean eGFR than the 2 AKI groups after 3 years (59.3±25.3 mL/min *vs.* 51±23.9 mL/min and 52.3±27.2 mL/min, respectively), whereas after 5 years, the only significant difference was between the Non-AKI and AKI-1 groups (58.6±26 mL/min *vs.* 51.1±24.7 mL/min).

Discussion
==========

Kidney transplantation is a life-saving treatment for many patients suffering from end-stage kidney failure. Many patients, however, receive transplantations unacceptably late due to the long waiting time for appropriate donor organs. In Germany in particular, this limitation has increasingly resulted in the acceptance and transplantation of organs from marginal donors, donors whose age is no longer limited by any maximal limit or those with accompanying diseases or a reduced kidney function. This delimitation of selection stringency, however, has made decision making in transplant medicine more challenging. Patients must be transplanted in a timely manner, but the acceptance of organs from marginal donor may compromise successful transplantation. The present study, in which successful renal transplantation was confirmed in 642 patients with almost half the patients (47.2%) having received an organ from donors with reduced kidney function, may provide a solution to this conflict. Importantly, the study revealed promising long-term results, comparable to those for organs meeting standard criteria.

Thus, in the present study, the main findings were: (i) the cumulative survival rates of patients and kidney grafts did not differ significantly among the groups at both the 1-year and 5-year assessments; (ii) no significant differences in survival rates were noted among the 3 groups in any of the assessments; (iii) further important parameters, such as mean SCr, mean eGFR, acute rejection episodes, and incidence of DGF, were also considered very promising.

It should be emphasized that in many transplant centers the acceptance of donor kidneys with impaired function remains highly restricted. For the 642 kidney-transplanted patients in our center a maximal SCr value of \>2 mg/dl was measured for 89 organ donors. In this group (AKI group 2), organ donors were younger, mostly male, and showed higher BMI. A constellation of factors that has also been associated with more promising kidney transplantation results in other studies \[[@b24-anntransplant-23-836]--[@b26-anntransplant-23-836]\]. It appears very likely that these factors actually contributed to organ acceptance, particularly in the case of young donors. For example, after traumatic death, recovery of kidney function can be expected, particularly in cases of short ischemia periods. In our own center, we have been reluctant to accept organs from elderly donors (\>65 years of age) with already impaired renal function and possible co-morbidities, such as diabetes mellitus, arterial hypertension, or proteinuria. Moreover, patients who received a functionally impaired renal transplant had significantly lower HLA matching rates. This may be because the patients may have received an organ that was ranked lower in the allocation list, as it had not been accepted at other transplantation centers, and this lower ranking could have been associated with an unfavorable HLA matching. These organs, having been rejected by other centers, were then accepted under the label of "rescue offer" or "center offer" with lower HLA matching stringency compared to those received via standard allocation. Notably, this was mostly observed when minimizing the ischemic time was a necessity and a donor kidney had to be accepted after AKI. Thus, it was not surprising that the ischemic period was shortest in the AKI-2 group (714.6±239.6 min), although the difference among groups was not significant. Each kidney transplant from a donor with AKI or other associated functional impairments had explicitly been discussed with the recipient before surgery. Notably, none of the patients refused transplantation, given the opportunity to terminate chronic dialysis treatment as soon as possible. However, this seems to reflect a lack of perspective after years of dialysis.

Kidneys derived from donors with AKI have also been successfully transplanted by other groups \[[@b13-anntransplant-23-836],[@b17-anntransplant-23-836]--[@b21-anntransplant-23-836],[@b27-anntransplant-23-836]--[@b29-anntransplant-23-836]\]. In this regard, some authors applied the risk, injury, failure, loss of function, end-stage renal disease classification \[[@b30-anntransplant-23-836]\] or Acute Kidney Injury Network criteria \[[@b31-anntransplant-23-836]\] to subdivide individual groups of donors with AKI. We decided not to use these criteria in the present study because laboratory results of many organ donors (n=106) were only available for one date; therefore, the course of the kidney's functional recovery could not be predicted. In a study by Jacobi et al. \[[@b32-anntransplant-23-836]\], 63 patients with AKI who could serve as kidney transplant donors were found among a total cohort of 382 brain-dead organ donors. The data were evaluated based on SCD (standard criteria donor) and ECD groups, with or without AKI. No significant difference in transplant survival was noted for either group between AKI and Non-AKI donors (SCD 91.8 *vs.* 91.3%; ECD 84.5 *vs.* 78.6%). In a further study involving 114 recipients of organs from donors with AKI (including 42 who had received organs from donors with severe AKI), comparable rates of patient and graft survival were seen at 1, 5, and 10 years \[[@b17-anntransplant-23-836]\]. In that study, the mean recipient and donor age was 37 years and the rate of ECD-type kidneys was 12.9%; thus, these results cannot be compared with those obtained in Germany. Interestingly, according to a retrospective analysis of the United Kingdom Transplant Registry published by Boffa et al. \[[@b15-anntransplant-23-836]\], among 11219 kidney transplantations investigated, 1869 organs were from donors with AKI. Transplant survival after 1 year was only 2% higher than that of organs from donors with AKI (91% *vs.* 89%). This slightly reduced transplant survival, however, may be negligible considering the otherwise prolonged time the patient would spend on the waiting list, with an annual death rate of 8.2%. Moreover, DGF rates increased with the AKI stage of the donor (from 28% to 55%) and PNF rates were significantly higher for donor kidneys with severe AKI, such as Acute Kidney Injury Network (AKIN) stage ≥3 (9% *vs.* 4%).

In the present study, the rate of DGF was highest in the AKI-2 group, indicating a larger proportion of subjects with acute tubular necrosis than in the AKI-1 group. In contrast, the mean donor serum creatinine concentration of 1.25 mg/dl at discharge in the AKI-1 group indicates a higher proportion of prerenal AKI in this group. The higher DGF rate in the AKI-2 group was consistent with that reported in previous studies, which also showed an increased DGF rate after transplantation of kidney grafts derived from donors with AKI. Hall et al. reported a DGF rate similar to the one in our Non-AKI group (28%), whereas the DGF rate proportionally increased from 34% to 57% with the severity of AKI \[[@b16-anntransplant-23-836]\]. Another study described DGF rates of 66% or 74% in patients who had received SCD or ECD kidneys from donors with AKI, respectively, as compared to a DGF rate of 27% in the Non-AKI group \[[@b20-anntransplant-23-836]\]. It is well known that the occurrence of DGF can be associated with an increased rate of acute organ rejection, a lower overall kidney function, as well as a lower rate of transplant survival \[[@b33-anntransplant-23-836]--[@b37-anntransplant-23-836]\]. Such diminished kidney function and survival rates, however, were not detected in the present investigation. On the contrary, both graft survival rates and kidney function in our study were similarly high in patients with and without DGF. Other research groups have reported similar results, whereby the occurrence of DGF after kidney transplantation impaired neither kidney survival nor kidney function \[[@b14-anntransplant-23-836],[@b17-anntransplant-23-836],[@b20-anntransplant-23-836],[@b21-anntransplant-23-836],[@b28-anntransplant-23-836],[@b38-anntransplant-23-836]\]. For example, Farney et al. showed that DGF in an AKI group had no measurable negative impact on transplant survival. In comparison, a significantly lower transplant survival was observed in a Non-AKI group \[[@b19-anntransplant-23-836]\]. Despite the higher rates of DGF in the AKI groups, we did not see an increased risk of rejection episodes within the first-year posttransplant.

As shown in the present study, PNF was more frequent in the AKI-1 and AKI-2 groups (approximately 10%) than in the non-AKI group (5.6%); however, this difference was not significant. The rate of PNF varies in the literature; for example, it ranged between 2.1% and 2.4% in the study by Farney et al. \[[@b19-anntransplant-23-836]\], and 1.5% and 10% in the study by Jacobi et al. \[[@b32-anntransplant-23-836]\]. In both reports, however, no correlation was found between PNF and the nature of AKI in the donor. The study by Boffa et al., on the other hand, reported that AKI, particularly AKIN stage 3 or higher, affected the occurrence of PNF \[[@b15-anntransplant-23-836]\].

Generally, potential recipients of kidneys from donors with AKI should be informed that permanent kidney non-function or early graft rejection might occur. In the present study, the provision of this information did not prompt any patient to refuse the transplantation. Besides this necessity to provide additional information, based on our results and those of a number of other research groups, we can confirm that the transplantation of grafts derived from donors with AKI can result in positive long-term results, significantly enlarging the available kidney donor pool.

Nevertheless, the acceptance of organs from donors with AKI remains a controversial issue. This point is substantiated by existing studies describing lower rates of kidney function and survival after transplantation of organs from donors with AKI \[[@b15-anntransplant-23-836],[@b22-anntransplant-23-836]\] despite the very limited quantitative disadvantage with respect to kidney function and survival of organs from donors with AKI reported by Boffa et al. \[[@b15-anntransplant-23-836]\]. Interestingly, Kolonko et al. described an impaired long-term functionality of kidneys from donors with AKI and an increased risk of transplant loss in an AKI group. Thus, the authors suggest restricting the use of organs from donors with AKI, particularly in the case of young recipients \[[@b22-anntransplant-23-836]\].

In the context of the present study, we continually tried to strictly follow our own center's strategies concerning the acceptance of organs derived from donors with AKI. These strategies aim to achieve early functional onset of the transplanted organs. Moreover, with these strategies we try to restrict the use of organs to those with short ischemic periods (\<12 hours), avoid warm ischemic periods by applying permanent ice-cooling systems during anastomosis, use T-cell-depleting antibodies to induce immunosuppression, and avoid calcineurin inhibitors during the early postoperative course. Nevertheless, this study had some limitations, as is typical of a retrospective, monocentric study. The etiology of kidney failure in the respective organ donors was multifactorial and has not been further evaluated. Moreover, we cannot fully exclude selection bias, since in many cases, the kidneys of donors with AKI had only been accepted when the donors presented no further risks and ischemic periods had been short. Finally, the AKI-2 group was slightly younger than the AKI-1 and the non-AKI groups. These limitations, however, must be considered in light of the described benefits, and future investigations must further clarify this debate based on additional data.

Conclusions
===========

Results of the present study suggest that donor kidneys from individuals with a history of AKI, although associated with a higher rate of DGF, result in long-term transplant acceptance and reliable kidney function after 5 years. Thus, the inclusion of donors with AKI may widely extend the pool of available donor organs; however, careful donor selection is necessary.

**Source of support:** Departmental sources
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###### 

Donor characteristics.

                                           Non-AKI-group (n=339)   AKI-1 group (n=214)   AKI-2 group (n=89)   
  ---------------------------------------- ----------------------- --------------------- -------------------- -------------------------------------------------------------------------------------------------------------------
  Age (years)                              55.28±16.08             56.91±15.68           49.31±16.34          p=0.001[2](#tfn2-anntransplant-23-836){ref-type="table-fn"},[3](#tfn3-anntransplant-23-836){ref-type="table-fn"}
                                                                                                              
  Gender                                                                                                      
   Female                                  206 (60.8)              82 (38.3)             19 (21.3)            p\<0.001
   Male                                    133 (39.2)              132 (61.7)            70 (78.7)            
                                                                                                              
  Cause of death                                                                                              
   cerebrovascular/cardiovascular          275 (81.1)              173 (80.8)            67 (75.3)            NS
   trauma                                  64 (18.9)               41 (19.2)             22 (24.7)            
                                                                                                              
  BMI (kg/m^2^)                            25.9±4.1                27.8±4.6              29.8±6.9             p\<0.001
                                                                                                              
  Preservation solution                                                                                       
   HTK                                     280 (82.6)              186 (86.9)            78 (87.6)            NS
   UW                                      57 (16.8)               28 (13.1)             7 (7.9)              
   Unknown/others                          2 (0.6)                 0 (0)                 4 (4.5)              
                                                                                                              
  Serum creatinine at admission (mg/dL)    0.75±0.18               1.08±0.29             1.42±0.51            p\<0.001
                                                                                                              
  Terminal serum creatinine (mg/dL)        0.73±0.19               1.25±0.32             2.8±1.31             p\<0.001
                                                                                                              
  Peak serum creatinine (mg/dL)            0.81±0.17               1.39±0.24             3.19±1.52            p\<0.001
                                                                                                              
  Urine production during last hour (mL)   178.8±159.3 (n=323)     189.2±117.2 (n=193)   147.9±106.9 (n=81)   p=0.012[1](#tfn1-anntransplant-23-836){ref-type="table-fn"},[2](#tfn2-anntransplant-23-836){ref-type="table-fn"}
                                                                                                              
  eGFR at admission (mL/min)               114.8±40.2              90.5±37.1             90.3±40.7            p\<0.001[1](#tfn1-anntransplant-23-836){ref-type="table-fn"},[3](#tfn3-anntransplant-23-836){ref-type="table-fn"}
                                                                                                              
  Terminal eGFR (mL/min)                   120.5±49.2              80.3±39.7             47.2±20.9            p\<0.001
                                                                                                              
  Renal replacement therapy                0 (0.0)                 1 (0.5)               9 (10.1)             p\<0.001[2](#tfn2-anntransplant-23-836){ref-type="table-fn"},[3](#tfn3-anntransplant-23-836){ref-type="table-fn"}
                                                                                                              
  Cardiac arrest                           42 (12.4)               86 (40.2)             56 (62.9)            p\<0.001
                                                                                                              
  Use of catecholamines                    292 (86.1)              185 (86.4)            83 (93.3)            NS
                                                                                                              
  History of diabetes                      24 (7.1)                37 (17.3)             12 (13.5)            p=0.001[1](#tfn1-anntransplant-23-836){ref-type="table-fn"}
                                                                                                              
  History of hypertension                  125 (36.9)              97 (45.3)             25 (28.1)            p=0.012[2](#tfn2-anntransplant-23-836){ref-type="table-fn"}
                                                                                                              
  Smoking                                  137 (40.4)              90 (42.1)             36 (40.4)            NS
                                                                                                              
  ECD                                      167 (49.3)              125 (58.4)            39 (43.8)            p=0.032[1](#tfn1-anntransplant-23-836){ref-type="table-fn"},[2](#tfn2-anntransplant-23-836){ref-type="table-fn"}

Significant difference between the Non-AKI group and the AKI-1 group;

Significant difference between the AKI-1 group and the AKI-2 group;

Significant difference between the Non-AKI-group and the AKI-2 group.

Values are given as mean ± standard deviation or n (% of group). Only p-values from the Kruskal-Wallis test are given. AKI -- acute kidney injury; BMI -- body mass index; ECD -- expanded criteria donors; eGFR -- estimated glomerular filtration rate; HTK -- histidine-tryptophan-ketoglutarate; NS -- not significant; UW -- University of Wisconsin solution.

###### 

Recipient characteristics.

                                    Non-AKI-group (n=339)   AKI-I group (n=214)   AKI-2 group (n=89)   
  --------------------------------- ----------------------- --------------------- -------------------- ------------------------------------------------------------------------------------------------------------------
  Age (years)                       54.6±12.9               56.2±13.0             55.6±11.4            NS
                                                                                                       
  Gender                                                                                               
   Male                             204 (60.2)              136 (63.6)            60 (67.4)            NS
   Female                           135 (39.8)              78 (36.4)             29 (32.6)            
                                                                                                       
  BMI (kg/m^2^)                     25.7±4.2                25.8±4.7              26.4±3.9             NS
                                                                                                       
  Time spent on dialysis (months)   78.3±45.2 (n=338)       76.3±45.9 (n=213)     84.0±39.5            NS
                                                                                                       
  Type of dialysis                                                                                     
   HD                               299 (88.2)              194 (90.7)            79 (88.8)            NS
   CAPD                             23 (6.8)                10 (4.7)              6 (6.7)              
   HD/CAPD                          14 (4.1)                9 (4.2)               4 (4.5)              
                                                                                                       
  CMV                                                                                                  
   R+/D+                            150 (44.2)              90 (42.0)             45 (50.5)            NS
   R+/D−                            83 (24.5)               58 (27.1)             21 (23.6)            
   R−/D+                            63 (18.6)               37 (17.3)             15 (16.9)            
   R−/D−                            43 (12.7)               29 (13.6)             8 (9.0)              
                                                                                                       
  HLA mismatch                      2.6±1.7                 3.0±1.7               2.9±1.5              p=0.014[1](#tfn5-anntransplant-23-836){ref-type="table-fn"}
                                                                                                       
  Highest PRA \>20%                 33 (9.7)                23 (10.8)             10 (11.2)            NS
                                                                                                       
  Cold ischemic time (min)          727.7±271.4             743.1±292.1           714.6±239.6          NS
                                                                                                       
  Operation time (min)              198.4±52.4 (n=328)      200.1±55.5 (n=201)    225.5±73.1 (n=87)    p=0.004[2](#tfn6-anntransplant-23-836){ref-type="table-fn"},[3](#tfn7-anntransplant-23-836){ref-type="table-fn"}
                                                                                                       
  Immunosuppressants                                                                                   
   ATG                              268 (79.1)              160 (74.8)            65 (73.0)            NS
   Tacrolimus                       305 (90.0)              178 (83.2)            77 (86.5)            
   CsA                              25 (7.4)                19 (8.9)              7 (7.9)              

Significant difference between the Non-AKI group and the AKI-1 group;

Significant difference between the AKI-1 group and the AKI-2 group;

Significant difference between the Non-AKI-group and the AKI-2 group.

Values are given as mean ± standard deviation or n (% of group). Only p-values from the Kruskal-Wallis test are given. ATG -- anti-thymocyte globulin; BMI -- body mass index; CAPD -- continuous ambulatory peritoneal dialysis; CMV -- cytomegalovirus; CsA -- cyclosporine A; D -- donor; HD -- haemodialysis; HLA -- human leucocyte antigen; NS -- not significant; PRA -- panel reactive antibodies; R -- recipient.

###### 

Results.

                                           Non-AKI group (n=339)   AKI-1 group (n=214)   AKI-2 group (n=89)   
  ---------------------------------------- ----------------------- --------------------- -------------------- ------------------------------------------------------------------------------------------------------------------
  Length of hospital stay (days)           33.4±39.1 (n=328)       31.0±27.8 (n=202)     30.6±15.7 (n=86)     NS
                                                                                                              
  Serum creatinine at discharge (mg/dL)    2.1±1.6 (n=323)         2.3±1.7 (n=198)       2.3±1.2 (n=83)       p=0.04[3](#tfn11-anntransplant-23-836){ref-type="table-fn"}
                                                                                                              
  Primary function                         223 (65.8)              128 (59.8)            40 (44.9)            p=0.001[2](#tfn6-anntransplant-23-836){ref-type="table-fn"},[3](#tfn7-anntransplant-23-836){ref-type="table-fn"}
                                                                                                              
  DGF                                      97 (28.6)               64 (29.9)             40 (44.9)            p=0.011[2](#tfn6-anntransplant-23-836){ref-type="table-fn"},[3](#tfn7-anntransplant-23-836){ref-type="table-fn"}
                                                                                                              
  PNF                                      19 (5.6)                22 (10.3)             9 (10.1)             NS
                                                                                                              
  1-year rejection                         89 (26.3)               63 (29.4)             23 (25.8)            NS
                                                                                                              
  Rejection grade (Banff)                                                                                     
   Borderline                              53 (59.5)               33 (52.4)             12 (52.2)            NS
   IA                                      15 (16.9)               10 (15.9)             3 (13.0)             
   IB                                      5 (5.6)                 4 (6.3)               2 (8.7)              
   IIA                                     15 (16.9)               14 (22.2)             6 (26.1)             
   IIB                                     1 (1.1)                 2 (3.2)               0                    
                                                                                                              
  Serum creatinine after 1 year (mg/dL)    1.81±1.13 (n=290)       2.08±1.7 (n=168)      2.01±1.52 (n=80)     NS
                                                                                                              
  eGFR after 1 year (mL/min)               55.44±23.26 (n=288)     51.16±23.45 (n=167)   56.46±23.63 (n=77)   NS
                                                                                                              
  Serum creatinine after 3 years (mg/dL)   1.65±0.77 (n=219)       2.18±2.1 (n=129)      2.3±2.23 (n=62)      p=0.001[1](#tfn5-anntransplant-23-836){ref-type="table-fn"},[3](#tfn7-anntransplant-23-836){ref-type="table-fn"}
                                                                                                              
  eGFR after 3 years (mL/min)              59.31±25.31 (n=218)     50.99±23.94 (n=129)   52.28±27.17 (n=62)   p=0.006[1](#tfn5-anntransplant-23-836){ref-type="table-fn"},[3](#tfn7-anntransplant-23-836){ref-type="table-fn"}
                                                                                                              
  Serum creatinine after 5 years (mg/dL)   1.7±0.88 (n=164)        1.91±1.28 (n=96)      1.74±0.66 (n=36)     NS
                                                                                                              
  eGFR after 5 years (mL/min)              58.56±26.04 (n=164)     51.06±24.65 (n=96)    57.44±31.21 (n=36)   p=0.049[1](#tfn9-anntransplant-23-836){ref-type="table-fn"}

Significant difference between the Non-AKI group and the AKI-1 group;

Significant difference between the AKI-1 group and the AKI-2 group;

Significant difference between the Non-AKI-group and the AKI-2 group.

Values are given as mean ± standard deviation or n (% of group). Only p-values from the Kruskal-Wallis test are given. AKI -- acute kidney injury; DGF -- delayed graft function; eGFR -- estimated glomerular filtration rate; NS -- not significant; PNF -- primary non-function.
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